Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGMT | P16455 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13695964 | 0.80 | MGLL (0.67) | MGMTMGLLABCG2CRBN | |
| SCHEMBL26349168 | 0.80 | MGMT (0.43) | MGMTMGLLABCG2GAA | |
| SCHEMBL27252888 | 0.80 | MGLL (0.67) | MGMTMGLLABCG2CRBN | |
| SCHEMBL25280932 | 0.80 | MGMT (0.43) | MGMTMGLLABCG2CRBNGAA | |
| SCHEMBL29009049 | 0.80 | MGLL (0.67) | MGMTMGLLABCG2CRBN | |
| SCHEMBL25495610 | 0.80 | MGLL (0.67) | MGMTMGLLABCG2CRBN | |
| SCHEMBL25495612 | 0.79 | MGMT (0.42) | MGMTMGLLABCG2 | |
| SCHEMBL18212282 | 0.77 | MGMT (0.40) | MGMTMGLLABCG2GAA | |
| SCHEMBL17262434 | 0.77 | MGMT (0.40) | MGMTMGLLABCG2GAA | |
| SCHEMBL30459733 | 0.75 | MGMT (0.39) | MGMTMGLLABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149541-B2 | Tyrosine ligation process | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-9149541-B2 | Tyrosine ligation process | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-9149541-B2 | Tyrosine ligation process | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-20140141034-A1 | TYROSINE LIGATION PROCESS | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140141034-A1 | TYROSINE LIGATION PROCESS | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140141034-A1 | TYROSINE LIGATION PROCESS | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | disclosed |
| EP-2729178-A1 | TYROSINE LIGATION PROCESS | Novartis AG (CH) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013009564-A1 | TYROSINE LIGATION PROCESS | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140141034-A1 | TYROSINE LIGATION PROCESS | ACP1, LTK, TTL | MGMT 3036/4885MGLL 327/4885ABCG2 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.